Get documents about "INNOVATORS IN DRUG DELIVERY
Description
INNOVATORS IN DRUG DELIVERY
Document Sample
ThE AusTrAliAN iNsTiTuTE FOr
BiOENgiNEEriNg ANd
NANOTEChNOlOgy
The Australian institute for
Bioengineering and Nanotechnology
(AiBN) is an exciting new research
institute that has moved beyond
traditional boundaries to focus
research effort into areas that
will be of great benefit to human
health, manufacturing, information
technology and the environment. Innovators In
The unique capabilities of the AIBN come from
drug delIvery
merging the skills of over 340 engineers, chemists,
biologists and computational scientists to conduct
world-class research programs in nano-scale
science, technology and engineering, coupled CONTACT
with a commitment to translating this research
To discuss the patent status and partnering opportunities
into commercial outcomes such as drug delivery. regarding these technologies or the development of others,
please contact:
The AIBN is located at The University of Queensland
Dr Craig Belcher
(UQ) which has a commitment to leadership in Manager of Innovation and Commercial Development
research and commercialization. The AIBN has full Australian Institute for Bioengineering and Nanotechnology (AIBN)
access to the resources and expertise of UniQuest,
UQ’s main technology commercialization company, The University of Queensland
Brisbane, Qld, Australia, 4072
ensuring all collaborating partners receive best
E: c.belcher@uniquest.com.au
practice service. UniQuest is recognized as one T: +61 7 3365 4037
of Australia’s largest and most highly-regarded F: +61 7 3365 4433
technology transfer groups taking university
research innovations to the global market. www.aibn.uq.edu.au
iNNOvATOrs ANd PArTNErs iN drug dElivEry FuNCTiONAl surFACEs – hydrOgEls FOr iN siTu
drug dElivEry
AIBN recognizes that all drugs are different and that some companies
need to find solutions to their drug delivery issues. AIBN has the capability to custom design wound healing and tissue
engineering materials for controlled delivery of small molecule
AIBN has a number of drug delivery technologies to suit, depending on therapeutics, anti-inflammatory agents, and growth factors using polymer
the nature of the drug or vaccine and the delivery needs. technologies built upon extensive knowledge of the physical chemistry of
polymer hydrogels and world-leading characterization capabilities.
Breadth of Our Technologies: Potential Benefits for you:
• Polymers (non-PEG) • Site-directed / controlled release Current targets are hydrogel-based products for:
• Nanoparticles • Solubility / toxicology • Delivery of growth factor complexes to deep wounds
• Virus-like particles • Enhanced vaccine immunogenicity (“The Bioactive Bandage”),
• Micro-nano projection patches • Pain-free vaccine delivery • In situ curable hydrogels for regeneration of bone tissue,
The active commercialization culture at the AIBN means that we are • Degradable networks for artificial blood vessels.
willing and able to partner with your company to build the value of your
product pipeline.
vlP – virus-likE ANTigEN disPlAy Nanopatch
AIBN researchers have developed scaleable technology for the display
of peptide antigen on a virus-like particle (VLP). VLPs exhibit strong
immunogenicity in a way not seen with simple peptide antigens. The NANOPATCh – PAiN FrEE vACCiNE dElivEry
dENdrimEd – drug dElivEry sOluTiON
immunological superiority of VLPs can be transferred to foreign peptide
FOr PrOBlEmATiC drugs The Nanopatch is comprised of thousands of tiny projections, invisible
antigen displayed on the surface of so-called chimeric VLPs.
to the human eye, which are dry-coated in biomolecules that, when
DendriMed provides drug delivery solutions for compounds with
By expressing large quantities of viral structural protein presenting the placed against the skin, deliver the biomolecules precisely to the
problematic solubility, physicochemical or toxicological characteristics.
selected vaccine sequence, highly purified quantities of the protein can targeted cells.
Designed for specificity and carrier functionality, the drug delivery be assembled in vitro into virus-like nanoparticles. The result is a non-
It offers significant advantages for vaccination programs in the developed
technology accommodates different charge, size and attached surface infectious particle that presents the selected vaccine sequence, initiating
and developing worlds by improving the ease of administration:
molecules (including targeting molecules), as well as enzymatic binding- a cascade of immunological responses.
based release. • Through the use of dehydrated vaccine that is
The technology for evaluation of specific peptide antigen of interest stable at ambient temperature, and
The DendriMed delivery macromolecule is designed from a “plug & play” is available and promises a low-cost route to immunoeffective
• By targeting the Langerhans cells of the skin, thereby initiating an
polymer library and is applicable to small molecules, peptides, protein or nanoparticles.
immune response without reaching the layer of cells that feel pain.
DNA/RNA with the ability to attach one or more drugs.
sAFE swAllOwiNg – BiOFluids &
NANOCOuriEr – EFFiCiENT ANd sAFE CEllulAr
BiOPOlymEr PrOCEssiNg
dElivEry vEhiClE
Oral delivery of drugs for swallowing-impaired patients (including
NanoCourier is an inorganic nanoparticle synthetically prepared with
elderly patients and children) will benefit from improved understanding
controlled size distribution, stability in suspension, and rich chemical
of the rheology and chemistry of biofluids.
properties for loading large numbers of anionic drugs. The material has
a long history of safe human oral administration. The biopolymer processing work uses polymer processing as a new
method for developing novel drug delivery systems for both oral
This platform technology enables the efficient cellular delivery
and localized delivery of drugs. This work focuses on smart design
and sustained release of anionic bioactive molecules and drugs,
of biopolymers, optimization of processing and control of final drug
oligonucleotides, low molecular weight heparins, and RNA/DNA
release kinetics.
segments, with a molecular weight of up to 10,000 Da.
Image Right: Virus-Like Particle
